GlassScriptPhysician profile
Rodney Fong
NPI 1679626360
$8,010.03
in general payments reported to CMS, 2019-2025
20 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $295 · 2021: $714 · 2022: $1,059 · 2023: $937 · 2024: $1,958 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Consulting Fee: $720 · Entertainment: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.50 |
| Consulting Fee | $720.00 |
| Entertainment | $129.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,413.31 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $901.39 | 2022-2025 | Infuse, Miebo, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $850.67 | 2019-2021 | |
| Alcon Vision LLC | $833.09 | 2019-2025 | Total30, Clareon Panoptix Pro |
| Aerie Pharmaceuticals, INC. | $717.53 | 2019 | |
| Glaukos Corporation | $592.37 | 2021-2025 | Photrexa Viscous and Photrexa, Istent Trabecular Micro-Bypass System Model Is3 |
| Coopervision INC. | $425.90 | 2019-2024 | Myday Contact Lens |
| Lkc Technologies, INC. | $371.50 | 2023-2025 | |
| Optos, INC. | $309.39 | 2021-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $251.50 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $239.85 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $200.33 | 2020-2023 | |
| Allergan, INC. | $174.30 | 2020-2022 | |
| Lombart Brothers, INC. | $141.19 | 2025 | Opd-III |
| Horizon Therapeutics Plc | $140.00 | 2023 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $117.38 | 2022 | |
| Abbvie INC. | $115.09 | 2022 | |
| Oyster Point Pharma, INC. | $103.35 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $94.69 | 2019 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Fong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.